Ventripoint is Now Listed on the OTCQB in the United States
Toronto, Ontario, October 24, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV: VPT, OTCQB: VPTDF) is pleased to announce that, as of October 23, 2018, the Company’s common shares are now trading on the OTCQB Venture Market for early stage and developing U.S. and international companies, under the stock symbol ‘VPTDF’. OTCQB companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and U.S. Over-the-Counter market information for the Company on www.otcmarkets.com.
OTCQB is recognized by the SEC as an established public market. OTCQB companies must provide current company financial information and news and meet financial standards that enable brokers to more easily quote and trade a security.
As a verified market with efficient access to U.S. investors, OTCQB will help Ventripoint to build shareholder value with a goal of enhancing liquidity and achieving fair valuation. It will allow the Company to engage a far greater network of U.S. investors, data distributors and media partners, ensuring U.S. investors have access to the same high-quality information that is available to investors in Canada, but through U.S. platforms and portals used to conduct research.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX Best Market, the OTCQB Venture Market and the Pink Open Market for 10,000 U.S. and global securities. Through OTC Link ATS and OTC Link ECN, it connects a diverse network of broker-dealers that provide liquidity and execution services. The Over-the-Counter Markets enable investors to easily trade through the broker of their choice and empowers companies to improve the quality of information available for investors.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.